SLC2A4 gene: a promising target for pharmacogenomics of insulin resistance

Abstract

PharmacogenomicsVol. 14, No. 8 EditorialFree AccessSLC2A4 gene: a promising target for pharmacogenomics of insulin resistanceMaria Lucia Corrêa-Giannella & Ubiratan F MachadoMaria Lucia Corrêa-GiannellaDepartment of Internal Medicine, Endocrinology & Laboratory for Cellular & Molecular Endocrinology (LIM-25), School of Medicine, University of São Paulo, São Paulo, BrazilSearch for more papers by this author & Ubiratan F Machado* Author for correspondenceDepartment of Physiology & Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil. Search for more papers by this authorEmail the corresponding author at ubiratan@icb.usp.brPublished Online:7 Jun 2013https://doi.org/10.2217/pgs.13.45AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit Keywords: diabetesGLUT4insulin resistancepharmacogenomicsSLC2A4The SLC2A4 geneThe GLUT4 protein, encoded by the solute carrier SLC2A4 gene in humans and Slc2a4 in mice and rats, is preferentially expressed in differentiated myotubes and adipocytes. Described in the early 1990s, GLUT4 is considered the insulin-sensitive glucose transporter based on its particular characteristic of being inserted in membranes of intracellular vesicles, which under insulin stimulus translocate to the plasma membrane, increasing the glucose uptake by these cells; the basis of postprandial glycemic control.Insulin-induced GLUT4 translocation is described as a much more robust phenomenon than it really is in vivo.In vitro translocation compares maximal insulin effect with the so-called basal condition in which insulin is absent. Whenever one tries to compare maximal insulin effect with basal physiological insulin concentrations, GLUT4 translocation is very low [1]. Besides, in skeletal muscle, GLUT4 translocation is also stimulated by muscle contraction, and contractile tonus is enough to induce great levels of translocation. However, a small relative translocation of GLUT4 (e.g., small percentage related to the total content) is able to significantly increase glucose uptake, avoiding impaired postprandial hyperglycemia. Unbelievably, several studies concerning GLUT4 translocation simply analyze the absolute amount of GLUT4 in plasma membrane. We point out that insulin induces vesicle translocation; and reduction in SLC2A4 expression (decreasing GLUT4 density in the vesicles) can explain decreased insulin-stimulated plasma membrane GLUT4 content, despite a preserved translocation system [2]. Finally, although some studies have proposed that molecular changes in the GLUT4 protein might alter its kinetics of transport, no consistent data has confirmed this hypothesis [3,4].Finally, SLC2A4/GLUT4 expression seems to be the main element in tissue glucose disposal; and, consequently, in glycemic homeostasis [5]. Considering that, investigations should focus on the regulation of SLC2A4/GLUT4 expression.SLC2A4 expression & insulin resistanceTo begin with, it is important to ponder that insulin resistance (IR) can be defined as and analyzed according to different points of view, without considering liver involvement. First, IR can be characterized in cells by detecting any impairment in the insulin signaling pathway, which not obligatorily results in impaired glucose uptake; adjustments in SLC2A4 expression and GLUT4 translocation can preserve normal glucose transport. Second, when SLC2A4/GLUT4 expression and insulin-induced glucose uptake are reduced in muscle and/or adipose cells, this does not guarantee that the plasma glucose clearance will be decreased; increased cellularity and/or tissue mass can counterbalance the cellular glucose disposal deficit. Finally, to infer about IR and impaired glycemic homeostasis, we need to analyze whole-body IR, defined by reduced insulin-induced plasma glucose clearance, for which total tissue GLUT4 content and consequently glucose disposal must be analyzed [6]. In non-obese subjects, skeletal muscle is the most important territory for insulin-induced glucose clearance; however, in obese subjects, adipose tissue can also become relevant.Remarkably, decreased insulin-induced glucose uptake, associated with impaired insulin signaling pathways, have been currently related only to impaired GLUT4 translocation; however, most studies in this context fail to demonstrate that decreased SLC2A4/GLUT4 expression is not concomitantly involved. Currently, these studies analyze only the absolute amount of plasma membrane GLUT4, without considering the total cell/tissue GLUT4 content. Thus, to understand the participation of SLC2A4/GLUT4 in cell/tissue/whole-body insulin-induced glucose clearance, different types of data analysis must be conducted [6].SLC2A4 expression in obesity & diabetesAs soon as the SLC2A4 gene was characterized, SLC2A4 mRNA and GLUT4 protein content were analyzed in obese and diabetic subjects, and controversial results were described. For instance, in obese IR subjects, SLC2A4 expression in adipose tissue was described as increased, unchanged and decreased. In experimental models of severely obese IR animals, GLUT4 was reduced in all insulin sensitive tissues [7], and treatments that improve glycemic homeostasis increased GLUT4 content. These data depict the important role of SLC2A4 in the pathophysiology of obesity and diabetes.Interestingly, studying the development of obesity and diabetes mellitus (DM) in monosodium-glutamate-treated mice, we observed in adipose tissue that, earlier, when fat gain mass is accelerated, Slc2a4 expression increases; however, later on, when progression of obesity stabilizes and severe IR is established, Slc2a4 expression decreases [8]. This pattern of Slc2a4 expression seems to be related to the inflammatory-induced NF-κB activity, a repressor of the Slc2a4 gene, and can explain the varied results of SLC2A4/GLUT4 expression reported in patients with obesity and Type 2 DM (T2DM).Additionally, several controversial data concerning the SLC2A4 gene and glycemic homeostasis were based only on SLC2A4 mRNA quantification, without GLUT4 protein analysis. However, we and others have reported discrepancies between regulation of Slc2a4 mRNA and GLUT4 protein. Data suggest that changes in Slc2a4 mRNA poly-A tail size, and in some specific miRNAs are involved in the post-transcriptional modulation of SLC2A4 expression, and investigations in this field should be strengthened.Nevertheless, nowadays it is well accepted that IR will culminate in decreased SLC2A4 expression, not only in obesity and T2DM, but also in pregnancy, gestational diabetes, polycystic ovary syndrome, some types of hypertension, the so-called metabolic syndrome and so on. Furthermore, although IR is not involved in the etiopathogeny of Type 1 DM, now we know that IR may also be present in such conditions; we have demonstrated in Type 1 DM rats that IR is accompanied by reduced GLUT4 content in skeletal muscle under both metabolically disturbed untreated and metabolically controlled hyperinsulinized situations [1].A better comprehension of the role of Slc2a4 expression in IR was gained when transgenic mice models were examined. At a glance, Slc2a4 knockout mice develop IR [9], and, conversely, Slc2a4 overexpression improves glycemic control of diabetic mice [10]. These data reinforce the fundamental role of SLC2A4 expression on glycemic homeostasis.In summary, increasing SLC2A4 expression would be desirable as a pharmacological treatment for IR/DM as much as decreasing SLC2A4 expression would be a valuable preventive approach against obesity.SLC2A4 pharmacogenetic basesExcept for a study in an Indian population in which the rs5435 SNP was associated with T2DM [11], and a previous genome-wide scan performed in caucasians that found the region harboring the SLC2A4 gene as associated with metabolic syndrome [12], variants in the SLC2A4 gene have been uncommonly associated with T2DM or obesity [13–15]. However, controlling SLC2A4 expression in target tissues, which can be modulated by genetic variants, is a promising intervention to treat these conditions.Because genes involved in glucose metabolism were described as over-represented among genes undergoing positive selection during human evolution [16], SCL2A4 diversity was investigated by sequencing SLC2A4 and genotyping 104 SNPs along an approximately 1 Mb region flanking this gene in ethnically diverse individuals (Africans, Europeans, Asians and Latin Americans) [17]. A total of 29 polymorphisms were detected. Located in the N-terminal region, upstream of exon 7, eight SNPs presenting a minor allele frequency (MAF) >5% in at least one population were identified (rs5415, rs5417 and rs5418 [5´-UTR]; rs222847, rs222849 and rs16956647 [intron 1]; rs5435 [exon 4] and rs5436 [intron 6]), along with another 15 SNPs with MAF <5%. On the other hand, the C-terminal region, downstream of intron 6, harbored only six SNPs with MAF <5%. The pattern of genetic variation in the N-terminal region (with common and rare variants) is compatible with neutral evolution, but the absence of common variants in the C-terminal region is compatible with natural selection decreasing the degree of substitution in this region [17]. The functional implications of these findings are unknown at the moment, but they might be relevant for comprehending SLC2A4 gene-expression control.To the best of the authors‘ knowledge, the only SLC2A4 SNP that has been functionally investigated is rs5418 (G/A); the A allele eliciting a higher luciferase activity in a gene reporter assay than the G allele and being over-represented in top-level long distance Chinese runners (61.8%) in comparison to healthy controls (45.6%) [18]. Interestingly, it was shown that healthy Japanese men who are homozygotes for the A allele of rs5418 presented significant lower HbA1c concentrations than AG+GG carriers [19]. Should these data be confirmed, one might ask whether T2DM carriers of the A allele could present a better metabolic response to exercise or even other therapeutic interventions known to increase SCL2A4 expression, such as glitazones.The synonymous rs5435 SNP, located in the SCL2A4 coding region and associated with T2DM in Indian patients [11], did not influence expression of SCL2A4 in muscle tissues of T2DM patients [20], but its relation with GLUT4 expression in adipose tissue was not evaluated. As is frequently the case in studies of genetic variants in polygenic conditions, the mechanisms underlying the association observed between rs5435 and T2DM is not known but could include changes in protein folding, linkage disequilibrium with other SNP able to destabilize pre-mRNA or activation of cryptic splicing sites, among others [11].The knowledge accumulated so far concerning SCL2A4 transcriptional regulation leads us to believe that pharmacogenomics has the potential to be applied to select subjects more or less prone to respond to therapeutic interventions that modulate GLUT4 expression. However, the future establishment of personalized insulin sensitizer therapy will require much more effort to further understand SCL2A4 biology.SummaryThe plain expression of the SLC2A4 gene, guaranteeing effective GLUT4 protein expression and the consequent insulin-induced glucose uptake by skeletal muscle and adipose tissue, plays a fundamental role on glycemic control. Insulin resistant condition, a feature of diabetes, is known to involve decreased SLC2A4 expression and to augment its expression, has a powerful insulin-sensitizer effect. This makes the SLC2A4 gene an important target for the pharmacogenomics of IR. Although variants in the SLC2A4 gene were not associated with diabetes and obesity in the past, recent studies have detected several SNPs in its flanking region. For instance, the rs5435 SNP was associated with T2DM, and the rs5418 SNP was associated with skeletal muscle performance and HbA1c levels. Thus, it is clear that pharmacogenomics has great potential to select subjects more or less prone to regulate the SLC2A4 gene and consequently glycemic homeostasis.Financial & competing interests disclosureThe authors acknowledge grants from FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), which have supported referenced studies from our research group in recent decades. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.References1 Okamoto MM, Anhê GF, Sabino-Silva R et al. Intensive insulin treatment induces insulin resistance in diabetic rats by impairing glucose metabolism-related mechanisms in muscle and liver. J. Endocrinol.211(1),55–64 (2011).Crossref, Medline, CAS, Google Scholar2 Machado UF, Shimizu I, Saito M. Reduced content and preserved translocation of glucose transporter (GLUT 4) in white adipose tissue of obese mice. Physiol. Behav.55(4),621–625 (1994).Crossref, Medline, CAS, Google Scholar3 Marsh BJ, Martin S, Melvin DR et al. Mutational analysis of the carboxy-terminal phosphorylation site of GLUT-4 in 3T3-L1 adipocytes. Am. J. Physiol.275(3),E412–E422 (1998).Medline, CAS, Google Scholar4 Zaarour N, Berenguer M, Le Marchand-Brustel Y, Govers R. Deciphering the role of GLUT4 N-glycosylation in adipocyte and muscle cell models. Biochem. J.445(2),265–273 (2012).Crossref, Medline, CAS, Google Scholar5 Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest.116(7),1767–1775 (2006).Crossref, Medline, CAS, Google Scholar6 Seraphim PM, Nunes MT, Machado UF. GLUT4 protein expression in obese and lean 12-month-old rats: insights from different types of data analysis. Braz. J. Med. Biol. Res.34(10),1353–1362 (2001).Crossref, Medline, CAS, Google Scholar7 Machado UF, Shimizu Y, Saito M. Decreased glucose transporter (GLUT 4) content in insulin-sensitive tissues of obese aurothioglucose- and monosodium glutamate-treated mice. Horm. Metab. Res.25(9),462–465 (1993).Crossref, Medline, CAS, Google Scholar8 de Carvalho Papa P, Vargas AM, da Silva JL, Nunes MT, Machado UF. GLUT4 protein is differently modulated during development of obesity in monosodium glutamate-treated mice. Life Sci.71(16),1917–1928 (2002).Crossref, Medline, Google Scholar9 Zisman A, Peroni OD, Abel ED et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med.6(8),924–9928 (2000).Crossref, Medline, CAS, Google Scholar10 Gibbs EM, Stock JL, McCoid SC et al. Glycemic improvement in diabetic db/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4). J. Clin. Invest.95(4),1512–1518 (1995).Crossref, Medline, CAS, Google Scholar11 Bodhini D, Radha V, Ghosh S, Majumder PP, Rao MR, Mohan V. GLUT4gene polymorphisms and their association with Type 2 diabetes in south Indians. Diabetes Technol. Ther.13(9),913–920 (2011).Crossref, Medline, CAS, Google Scholar12 Kissebah AH, Sonnenberg GE, Myklebust J et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc. Natl Acad. Sci. USA97(26),14478–14483 (2000).Crossref, Medline, CAS, Google Scholar13 Choi WH, O‘Rahilly S, Buse JB et al. Molecular scanning of insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes40(12),1712–1718 (1991).Crossref, Medline, CAS, Google Scholar14 Lesage S, Zouali H, Vionnet N et al. Genetic analyses of glucose transporter genes in French non-insulin-dependent diabetic families. Diabetes Metab.23(2),137–142 (1997).Medline, CAS, Google Scholar15 Friedel S, Antwerpen B, Hoch A et al. Glucose transporter 4 gene: association studies pertaining to alleles of two polymorphisms in extremely obese children and adolescents and in normal and underweight controls. Ann. NY Acad. Sci.967,554–557 (2002).Crossref, Medline, CAS, Google Scholar16 Haygood R, Fedrigo O, Hanson B, Yokoyama KD, Wray GA. Promoter regions of many neural- and nutrition-related genes have experienced positive selection during human evolution. Nat. Genet.39(9),1140–1144 (2007).Crossref, Medline, CAS, Google Scholar17 Tarazona-Santos E, Fabbri C, Yeager M et al. Diversity in the glucose transporter-4 gene (SLC2A4) in humans reflects the action of natural selection along the old-world primates evolution. PLoS ONE5(3),1–10 (2010).Crossref, Google Scholar18 Xia X, Hu Y, Xu L, Chen T. A functional promoter polymorphism of SLC2A4 is associated with aerobic endurance in a Chinese population. Eur. J. Sport Sci.2012,1–7 (2012).Crossref, Google Scholar19 Xi C, Miyaki K, Ikeda S, Song Y, Sinbo T, Muramatsu M. Association of GLUT4 gene variants with HbA1c level in Japanese men. Endocr. J.59(8),677–684 (2012).Crossref, Medline, CAS, Google Scholar20 Bjørbaek C, Echwald SM, Hubricht P et al. Genetic variants in promoters and coding regions of the muscle glycogen synthase and the insulin-responsive GLUT4 genes in NIDDM. Diabetes43(8),976–983 (1994).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByRegulation and mechanism of action of miRNAs on insulin resistance in skeletal musclesNon-coding RNA Research, Vol. 8, No. 2Genome-wide methylome and transcriptome dynamics provide insights into epigenetic regulation of kidney functioning of large yellow croaker (Larimichthys crocea) during low-salinity adaptionAquaculture, Vol. 571Fatty Acid Induced Hypermethylation in the Slc2a4 Gene in Visceral Adipose Tissue Is Associated to Insulin-Resistance and Obesity29 March 2023 | International Journal of Molecular Sciences, Vol. 24, No. 7Co-expression analysis of lncRNA and mRNA identifies potential adipogenesis regulatory non-coding RNAs involved in the transgenerational effects of tributyltin3 February 2023 | PLOS ONE, Vol. 18, No. 2Biochemical Activation and Regulatory Functions of Trans-Regulatory KLF14 and Its Association with Genetic Polymorphisms29 January 2023 | Metabolites, Vol. 13, No. 2Metallic Vessel with Mesh Culture Surface Fabricated Using Three-dimensional Printing Engineers Tissue Culture Environment30 January 2023 | Biotechnology and Bioprocess Engineering, Vol. 28, No. 1GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems26 January 2022 | Scientific Reports, Vol. 12, No. 1Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport23 January 2022 | International Journal of Molecular Sciences, Vol. 23, No. 3AGEs-Induced and Endoplasmic Reticulum Stress/Inflammation-Mediated Regulation of GLUT4 Expression and Atherogenesis in Diabetes Mellitus29 December 2021 | Cells, Vol. 11, No. 1Reversible insulin resistance helps Bactrian camels survive fasting22 September 2021 | Scientific Reports, Vol. 11, No. 1Establishment of long-term high-fat diet and low dose streptozotocin-induced experimental type-2 diabetes mellitus model of insulin resistance and evaluation of seed extracts of Syzygium cumini2 July 2021 | Journal of Herbmed Pharmacology, Vol. 10, No. 3miR-335-5p aggravates type 2 diabetes by inhibiting SLC2A4 expressionBiochemical and Biophysical Research Communications, Vol. 558Glucocorticoid Receptor Alpha Targets SLC2A4 to Regulate Protein Synthesis and Breakdown in Porcine Skeletal Muscle Cells12 May 2021 | Biomolecules, Vol. 11, No. 5Dynamic flux balance analysis of whole-body metabolism for type 1 diabetes24 May 2021 | Nature Computational Science, Vol. 1, No. 5[18F]FDG Uptake in Adipose Tissue Is Not Related to Inflammation in Type 2 Diabetes Mellitus4 September 2020 | Molecular Imaging and Biology, Vol. 23, No. 1Estrogen and Glycemic Homeostasis: The Fundamental Role of Nuclear Estrogen Receptors ESR1/ESR2 in Glucose Transporter GLUT4 Regulation7 January 2021 | Cells, Vol. 10, No. 1SLC2A4 expression and its epigenetic regulation as biomarkers for insulin resistance treatment in diabetes mellitusJoão V Esteves, Caio Y Yonamine & Ubiratan F Machado6 April 2020 | Biomarkers in Medicine, Vol. 14, No. 6RNA-sequencing analysis reveals the potential contribution of lncRNAs in palmitic acid-induced insulin resistance of skeletal muscle cells2 January 2020 | Bioscience Reports, Vol. 40, No. 1Indirubin promotes adipocyte differentiation and reduces lipid accumulation in 3T3‑L1 cells via peroxisome proliferator‑activated receptor γ activation16 January 2020 | Molecular Medicine ReportsEstradiol stimulates adipogenesis and Slc2a4/GLUT4 expression via ESR1-mediated activation of CEBPAMolecular and Cellular Endocrinology, Vol. 498Taurine protects against arsenic trioxide-induced insulin resistance via ROS-Autophagy pathway in skeletal muscleThe International Journal of Biochemistry & Cell Biology, Vol. 112Carbenoxolone enhances peripheral insulin sensitivity and GLUT4 expression in skeletal muscle of obese rats: Potential participation of UBC9 proteinLife Sciences, Vol. 229Diabetes induces tri-methylation at lysine 9 of histone 3 at Slc2a4 gene in skeletal muscle: A new target to improve glycemic controlMolecular and Cellular Endocrinology, Vol. 481Advanced glycation end products-induced insulin resistance involves repression of skeletal muscle GLUT4 expression25 May 2018 | Scientific Reports, Vol. 8, No. 1Diabetes Modulates MicroRNAs 29b-3p, 29c-3p, 199a-5p and 532-3p Expression in Muscle: Possible Role in GLUT4 and HK2 Repression12 September 2018 | Frontiers in Endocrinology, Vol. 9Type 2 Diabetes Treatment and Drug Development StudyThe Open Diabetes Journal, Vol. 8, No. 1Type 2 Diabetes Study, Introduction and PerspectiveThe Open Diabetes Journal, Vol. 8, No. 1Emerging Role of MicroRNA in Diabetes MellitusTransient gestational exposure to drinking water containing excess hexavalent chromium modifies insulin signaling in liver and skeletal muscle of rat progenyChemico-Biological Interactions, Vol. 277Estradiol-induced regulation of GLUT4 in 3T3-L1 cells: involvement of ESR1 and AKT activationJournal of Molecular Endocrinology, Vol. 59, No. 3Resveratrol Improves Glycemic Control in Type 2 Diabetic Obese Mice by Regulating Glucose Transporter Expression in Skeletal Muscle and Liver14 July 2017 | Molecules, Vol. 22, No. 7MicroRNAs-Mediated Regulation of Skeletal Muscle GLUT4 Expression and Translocation in Insulin ResistanceJournal of Diabetes Research, Vol. 2017Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory29 June 2016 | Nutrition & Metabolism, Vol. 13, No. 1Lipids Nutrition and Epigenetic Modification in Obesity-Related Co-Morbitities * *All authors equally contributed to draft the manuscript. All authors gave final approval of the version to be published. Disclosure statement: The authors declare that there are no conflicts of interest.Lipids, Low-Grade Chronic Inflammation and NAFLDBeta-adrenergic blockade increases GLUT4 and improves glycemic control in insulin-treated diabetic Wistar ratsAutonomic Neuroscience, Vol. 193Oleic and linoleic fatty acids downregulate Slc2a4/GLUT4 expression via NFKB and SREBP1 in skeletal muscle cellsMolecular and Cellular Endocrinology, Vol. 401Decreased diabetes-induced glycemic impairment in WKY and SHR involves enhanced skeletal muscle Slc2a4/GLUT4 expression10 September 2014 | Diabetology & Metabolic Syndrome, Vol. 6, No. 1Insulin acutely triggers transcription of Slc2a4 gene: Participation of the AT-rich, E-box and NFKB-binding sitesLife Sciences, Vol. 114, No. 1 Vol. 14, No. 8 Follow us on social media for the latest updates Metrics History Published online 7 June 2013 Published in print June 2013 Information© Future Medicine LtdKeywordsdiabetesGLUT4insulin resistancepharmacogenomicsSLC2A4Financial & competing interests disclosureThe authors acknowledge grants from FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo), which have supported referenced studies from our research group in recent decades. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download